Kerri Ann Law is an experienced trial lawyer and counselor with a diverse practice representing clients, including Fortune 500 companies, in complex commercial litigation in both state and federal courts, as well as in domestic and international arbitration forums. She also represents companies and individuals in connection with sensitive and high-profile criminal and regulatory matters and related civil matters. On behalf of her clients, Kerri Ann regularly interacts with the Securities and Exchange Commission, the U.S. Department of Justice, the Manhattan District Attorney’s Office and other governmental agencies.
Among her more notable representations, Kerri Ann secured a multimillion-dollar jury victory for a manufacturing company in an unfair competition case in which the jury found that the defendant had stolen trade secrets relating to unique and state-of-the-art manufacturing processes that the plaintiff had developed over decades. She also represented Bear Stearns in several shareholder derivative actions and class actions arising from the collapse of two hedge funds in 2007, and an individual in a putative class action alleging manipulation of the platinum and palladium markets, including the trading of futures contracts, in violation of the Commodity Exchange Act, the Sherman Antitrust Act, and the Racketeer Influenced and Corrupt Organizations Act.
Kerri Ann has litigated numerous false advertising matters for pharmaceutical and other companies, including successfully defending AstraZeneca in a false advertising suit related to the company’s Nexium product.
Kerri Ann undertakes many pro bono matters, with a particular focus on human rights. She successfully obtained asylum for a woman who had been repeatedly persecuted in Kosovo and Montenegro because of her nationality and her religious and political opinions. She serves on the firm’s Operating Committee, Planning Committee, Branding Committee and Women’s Initiative Committee, and as chair of the firm’s Hiring Committee. She also regularly serves on the firm’s Compensation Committee.
Updated Aug 2023
